Ocular Surface Disease and Glaucoma Treatments

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 3897

Special Issue Editor


E-Mail Website
Guest Editor
Department of Surgical, Medical, Molecular Pathology and of Critical Area—University of Pisa, Pisa, Italy
Interests: glaucoma; ocular surface; anterior segment surgery; uveitis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Glaucoma treatments include medical, surgical and laser therapies. Usually, medications represent first-line therapy even if an ocular surface disease may develop due to years of treatment, the number of eye drops, preservatives, age or previous conditions. Today, more attention is paid to the ocular surface and how quality of life could be affected by medications more than by visual field defects in the early stages of disease. Therefore, in the last few years, the literature about the study of ocular surface disease and glaucoma using new diagnostic tools has increased. Many laboratory tests have been introduced to highlight the immunological changes and inflammation in the ocular surface. Anterior segment-optical coherence tomography and in vivo confocal microscopy have been largely used to detect the early signs of ocular surface alterations and the relationship between the ocular surface and failure of filtering surgery. This is still an unsolved issue. Multidose eye drops require preservatives to prevent microbial contamination. Preservatives disrupt the ocular surface and tear film generation or increase pre-existing ocular surface disease. Recently, preservative-free eye drops, both unidose and multidose formulations, and new slow-release devices have been introduced to improve ocular surface health. Besides, laser trabeculoplasty or minimally invasive glaucoma surgery are anticipated to become more widespread in surgical treatment to replace standard anterior filtering surgery.

The purpose of this Special Issue is to illustrate the new developments that are taking place in terms of ocular surface disease diagnosis and improvements in glaucoma patients.

Dr. Michele Figus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Ocular surface
  • Glaucoma
  • MIGS
  • Inflammation
  • Tear film
  • Medical treatment
  • Anterior segment OCT
  • On vivo confocal microscopy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 1554 KiB  
Review
Confocal Microscopy and Anterior Segment Optical Coherence Tomography Imaging of the Ocular Surface and Bleb Morphology in Medically and Surgically Treated Glaucoma Patients: A Review
by Carmela Carnevale, Ivano Riva, Gloria Roberti, Manuele Michelessi, Lucia Tanga, Alice C. Verticchio Vercellin, Luca Agnifili, Gianluca Manni, Alon Harris, Luciano Quaranta and Francesco Oddone
Pharmaceuticals 2021, 14(6), 581; https://doi.org/10.3390/ph14060581 - 18 Jun 2021
Cited by 7 | Viewed by 3271
Abstract
Glaucoma patients often suffer from ocular surface disease (OSD) caused by the chronic administration of topical anti-glaucoma medications, especially in cases of long-term therapy with preserved or multiple drugs. Additionally, glaucoma surgery may determine ocular surface changes related to the formation and location [...] Read more.
Glaucoma patients often suffer from ocular surface disease (OSD) caused by the chronic administration of topical anti-glaucoma medications, especially in cases of long-term therapy with preserved or multiple drugs. Additionally, glaucoma surgery may determine ocular surface changes related to the formation and location of the filtering bleb, the application of anti-mitotic agents, and the post-operative wound-healing processes within the conjunctiva. Recently, several studies have evaluated the role of advanced diagnostic imaging technologies such as in vivo confocal microscopy (IVCM) and anterior segment-optical coherence tomography (AS-OCT) in detecting microscopic and macroscopic features of glaucoma therapy-related OSD. Their clinical applications are still being explored, with recent particular attention paid to analyzing the effects of new drug formulations and of minimally invasive surgical procedures on the ocular surface status. In this review, we summarize the current knowledge about the main changes of the ocular surface identified at IVCM and AS-OCT in glaucoma patients under medical therapy, or after surgical treatment. Full article
(This article belongs to the Special Issue Ocular Surface Disease and Glaucoma Treatments)
Show Figures

Figure 1

Back to TopTop